Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

nt and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone differ in some respects from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone and there can be no assurance that the U.S. or European regulatory authorities will approve the use of pirfenidone for the treatment of IPF; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.

Actimmune(R) is a registered trademark of InterMune, Inc. Pegasys(R) and Copegus(R) are registered trademarks of Roche.

                           Financial tables follow



                               InterMune, Inc.
         PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
             (unaudited, in thousands, except per share amounts)

                                Three Months Ended      Year Ended
                                      Dec 31              Dec 31
                                   2008      2007      2008      2007
    Revenue, net
      Actimmune                   $6,583    $8,809   $29,880   $53,420
      Collaboration revenue          818       81
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... , Aug. 18, 2014 ... of advanced consumer medical devices said that ... was interviewed by CEOLIVE.TV as part of ... entire interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... Kotak explains to investors the unique advantages ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... 16 NanoSmart™ Pharmaceuticals, Inc., a California corporation developing ... received a Notice of Allowance for a US patent ... "We have taken an approach to targeting tumors that ... CEO of the company. "While most of cancer research ...
... Announces Record Second Quarter 2010 Results -- HARBIN, China, Aug. 16 /PRNewswire-Asia/ -- ... ... --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... Aug. 16 NeoStem, Inc. (NYSE Amex: ... company with product and service revenues, global research and ... U.S. adult stem cells, China adult stem cells, and ... quarter 2010. Second Quarter Results ...
Cached Biology Technology:NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology 2Nutrastar International Inc. Announces Record Second Quarter 2010 Results 2Nutrastar International Inc. Announces Record Second Quarter 2010 Results 3Nutrastar International Inc. Announces Record Second Quarter 2010 Results 4Nutrastar International Inc. Announces Record Second Quarter 2010 Results 5Nutrastar International Inc. Announces Record Second Quarter 2010 Results 6Nutrastar International Inc. Announces Record Second Quarter 2010 Results 7Nutrastar International Inc. Announces Record Second Quarter 2010 Results 8Nutrastar International Inc. Announces Record Second Quarter 2010 Results 9Nutrastar International Inc. Announces Record Second Quarter 2010 Results 10NeoStem Provides Second Quarter Update 2NeoStem Provides Second Quarter Update 3NeoStem Provides Second Quarter Update 4
(Date:8/20/2014)... In leaves, photosystem 1 (PS1) absorbs light and ... of carbon dioxide to biomass. Photovoltaic devices, mostly ... light but produce electricity. One approach for the ... replacing the semi-conductor with the isolated membrane protein ... isolates a highly stable PS1 from thermophilic cyanobacteria ...
(Date:8/20/2014)... Aug. 20, 2014  The second annual Biometrics ... Tampa, Florida on September ... Steven Rahman, Director, Technology and Strategy at Samsung, and ... The theme of this year,s event is Mobility ... "Biometrics UnPlugged: Mobility at the Crossroads ...
(Date:8/19/2014)... students, chances of completing introductory biology courses and ... implemented a comprehensive student success program, employing various ... , Through a grant from the Texas Higher ... and Biochemistry embarked on a pilot program focusing ... and "Introductory Biology" for science majors. These two ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... The Press Room will be on the fifth floor of ... the Main Lecture Room, offering free wireless access, the book ... January 6 through Friday, January 8, 7:30 a.m.-5:00 p.m., and ... press is free. Two events are open to the ...
... glioma, the most common primary brain tumor, new findings ... cancer. A UCSF-led team of scientists has identified ... stem cells underly a type of glioma called oligodendroglioma. ... to therapy than other brain tumors such as glioblastoma ...
... the allergic reactions that asthmatics suffer towards a common ... had the mould growing in their own lungs. ... Glenfield Hospital has been published in the December 2010 ... Critical Care Medicine . The team based in ...
Cached Biology News:Joint Mathematics Meetings in New Orleans Jan. 6-9 2Joint Mathematics Meetings in New Orleans Jan. 6-9 3Joint Mathematics Meetings in New Orleans Jan. 6-9 4Joint Mathematics Meetings in New Orleans Jan. 6-9 5Joint Mathematics Meetings in New Orleans Jan. 6-9 6Joint Mathematics Meetings in New Orleans Jan. 6-9 7Cell of origin for brain tumors may predict response to therapy 2Cell of origin for brain tumors may predict response to therapy 3New asthma research breaks the mold 2
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... Dot Blot Kits overcome this limitation and ... a wide range in low-density protein array ... They are ideal for performing reverse-phase protein ... for the presence of low abundant antigens. ...
AC input: 50-60 Hz230 V...
... arraying proteins of interest with sensitive ... DiscoverLight Protein Array Kits allow for ... lysate or antibody in a low-density ... designed nitrocellulose membranes with a 384-grid ...
Biology Products: